Evaluating the Effects of VQW-765 vs. Placebo in Performance Anxiety

Vanda Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Performance Anxiety

Treatments: Drug: VQW-765; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT04800237

VP-VQW-765-2201

Details and patient eligibility

About

This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single oral dose of VQW-765 compared to placebo in male and female participants with performance anxiety.

Enrollment: 230 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Ability and willingness to provide written informed consent.
• Sufficiently fluent in English to participate in the trial.
• Male and female patients aged 18-70 years (inclusive).

Exclusion criteria

• Lifetime history of bipolar disorder, schizophrenia, psychosis, seizures, delusional disorders or obsessive-compulsive disorder.
• Current or planned pregnancy or nursing during the trial period.
• A positive test for substances of abuse.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

230 participants in 2 patient groups, including a placebo group

VQW-765

Experimental group

Treatment:

Drug: VQW-765

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo